US Stock Market Closed

Dashboard

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

CEO

John V. Oyler

Employees

3,500

Industry

-

Sector

-

Headquarters

-

Exchange

NASDAQ

Summary Stats

Market Cap

14.4B

Revenue

1.07B

Net Income

-2.01B

EPS

-$20.68

Price-to-Earnings

-6.7

Price-to-Book

2.71

Debt-to-Equity

0.39

News

Analyst Ratings

Price targets projected by 15 analysts

High

$359.00

Average

$297.20

Low

$135.00

Ratings calculated by 17 analysts

Buy

11

Hold

5

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Missed by -$1.59

Actual

-$5.56 -40.1%

Consensus

-3.97

Report Date

Year Ago

-5.23

Year Ago Change %

Down 6%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites